Full Text
Cost-Effectiveness of Eml4-Alk Gene Targeted First-Line Ceritinib Treatment Among Patients With Advanced Alk-Positive Non–Small Cell Lung Cancer

Abstract

Authors

N. Upadhyay N. Atreja

Back to Volume 18, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×